Micofenolato De Mofetilo Stada (Mycophenolate Mofetil)

Mycophenolate Mofetil is used in immunosuppressive regimens targeting organ transplantation and autoimmune kidney disease.

• Acute organ transplant rejection: helps prevent rejection episodes after solid‑organ transplantation.
• Kidney transplant: reduces the risk of graft loss and improves long‑term graft survival.
• Lupus nephritis: diminishes renal inflammation and slows disease progression in systemic lupus erythematosus patients.

• Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This blockade curtails guanosine nucleotide synthesis, a pathway essential for lymphocyte proliferation, thereby suppressing the immune response without markedly affecting other cell types.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: frequent loose stools, sometimes leading to dehydration.
• Headache: transient cranial discomfort.
• Abdominal pain: cramping or discomfort in the stomach area.
• Vomiting: occasional emesis, especially after dose initiation.
• Infections: increased susceptibility to bacterial, viral, or fungal infections.

Serious or Rare Side Effects

• Leukopenia: significant reduction in white blood cell count.
• Anemia: decreased red blood cell levels causing fatigue.
• Severe infections: opportunistic infections such as Pneumocystis jirovecii pneumonia.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Malignancy risk: potential increased risk of lymphoproliferative disorders.
• Progressive multifocal leukoencephalopathy (PML): rare but life‑threatening brain infection.

Patients receiving Mycophenolate Mofetil should be monitored closely for safety and efficacy.

• Blood counts: monitor complete blood count regularly to detect leukopenia or anemia.
• Renal function: assess serum creatinine and glomerular filtration rate, especially in transplant recipients.
• Pregnancy: avoid use during pregnancy; drug is classified as Category D.
• Contraception: ensure effective contraception for both male and female patients of reproductive potential.
• Drug interactions: review concomitant medications that may affect mycophenolate exposure.
• Storage: Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil interacts with several agents that may alter its efficacy or safety.

Major Interactions (Avoid)

• Azathioprine: additive bone‑marrow suppression.
• Cyclosporine or tacrolimus: increased risk of nephrotoxicity and infections.
• Cholestyramine or colestipol: reduces oral absorption of mycophenolic acid.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may potentiate renal impairment.
• Warfarin: possible alteration of anticoagulant effect.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of gastrointestinal irritation.
• Live vaccines: heightened risk of vaccine‑derived infection.